Consortium to Develop Fully Implantable Brain-Computer Interface to Enable Communication for People with Paralysis

A research consortium led by the UMC Utrecht Brain Center (the Netherlands) in collaboration with Graz University of Technology (Austria), the Wyss Center for Bio and Neuroengineering (Switzerland) and CorTec (Germany) is to receive a grant through the European Innovation Council (EIC) Pathfinder Challenge mechanism.

The researchers aim to develop a unique fully implantable Brain-Computer Interface (BCI) system for people with locked-in syndrome (LIS) - a condition in which paralysis severely limits communication. The BCI will be unprecedented in its small size, wireless and powered via induction so will not require batteries. Suitable for use at home, it will be capable of decoding speech in real-time to enable people with LIS to communicate with family and caregivers.

The project will further develop the Wyss Center’s fully implantable wireless ABILITY system to connect to customized electrocorticography (ECoG) electrode grids, developed by CorTec, that detect brain signals from the surface of the brain. The ambitious timeline aims for full implant development and verification in the first two years of the project, with the second two years focusing on clinical studies and algorithm improvements to restore communication in locked-in patients with amyotrophic lateral sclerosis (ALS) or brainstem stroke. ALS is a progressive neurodegenerative disease in which people gradually lose the ability to move and talk, eventually all means of communication are lost, leaving patients isolated. Brainstem stroke can render people unable to speak or move, without recovery.

"As a first step to enable the patients to interact with the system, we will set up the decoding for mouse clicks and cursor control from intended movements, which we have shown to be feasible in previous research," explains Prof. Dr. Gernot Müller-Putz, Head of the Institute of Neural Engineering and its associated Laboratory of Brain-Computer Interfaces at the Graz University of Technology.

"Our BCI system will go far beyond current technology," says Prof. Nick Ramsey from the UMC Utrecht Brain Center, the Netherlands, who coordinates the project. "We want to create a sustainable, high-resolution BCI by combining state-of-the-art hardware and software based on artificial intelligence (AI)."

"This new project builds on the promising preliminary data from our clinical study enabling communication with a completely locked-in participant, and our pre-clinical study currently underway with the wireless, implantable ABILITY device." said Dr. Jonas Zimmermann, Senior Neuroscientist at the Wyss Center. "In this project we will record from a larger area of the brain and explore new decoding algorithms that have the potential to tackle important clinical and social needs for people with ALS but also for those with other neurological conditions that impair movement and communication."

Dr. Tracy Laabs, Chief Development Officer at the Wyss Center, is excited: "After several years of prototype developments, this project will allow us to make the crucial final steps that will bring our system to the patient."

The BCI system will be trialed in two people with locked-in syndrome in the home environment. The brain surface-lining electrode grids will collect high resolution neural data that will be decoded using AI algorithms to translate the brain signals to computer speech in real-time.

The research project 'Intracranial Neurotelemetry to Restore Communication' (INTRECOM) is part of the EIC Pathfinder Challenge program in which the European Innovation Council supports visionary, entrepreneurial researchers who have bold ideas for radically new technologies. The Swiss participants receive support from the Swiss State Secretariat for Education, Research and Innovation (SERI).

About the Wyss Center for Bio and Neuroengineering

The Wyss Center is an independent, non-profit, research and development organization that advances our understanding of the brain to realize therapies and improve lives.

The Wyss Center staff, together with the Center's academic, clinical and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroimaging and neurotechnology.

Wyss Center advances reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease to accelerate the development of devices and therapies for unmet medical needs.

The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.

http://www.wysscenter.ch

Most Popular Now

The Future of Medicine is Data

At the 2023 Annual J.P. Morgan Healthcare Conference, Owkin Co-founder and CEO Thomas Clozel, MD will outline how data is the future of medicine - from the development of new...

Study Surveys Landscape of Apps Built on…

A study led by Regenstrief Institute Research Scientist Titus K. Schleyer, DMD, PhD, is among the first to survey the current landscape of FHIR® apps, providing a snapshot of how...

New Computer Program 'Learns' to Identif…

Genetic mutations cause hundreds of unsolved and untreatable disorders. Among them, DNA mutations in a small percentage of cells, called mosaic mutations, are extremely difficult to detect because they exist...

Applications Open for SpinLab Accelerato…

The start-up accelerator supports entrepreneurial and innovative teams that want to grow sustainably and successfully scale their business model. With a strong hands-on mentality and a lot of passion, the...

Bayer to Accelerate Drug Discovery with …

Bayer AG and Google Cloud today announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run...

Allscripts Announces Corporate Name Chan…

Allscripts Healthcare Solutions, Inc. announced that, effective January 1, 2023, it has changed its name to Veradigm Inc. (NASDAQ: MDRX). Allscripts had been transitioning its solutions to the Veradigm brand...

220M€ Investment in Testing and Experime…

To make the EU the place where AI excellence thrives from the lab to the market, the European Union is setting up world-class Testing and Experimentation Facilities (TEFs) for AI. Together...

AI Tool Developed to Predict Risk of Lun…

Lung cancer is the leading cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is recommended to screen people between 50 and...

Artificial Nerve Cells - Almost Like Bio…

Researchers at Linköping University (LiU), Sweden, have created an artificial organic neuron that closely mimics the characteristics of biological nerve cells. This artificial neuron can stimulate natural nerves, making it...

Bayer Acquires Blackford Analysis Ltd. B…

Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The acquisition is part of Bayer's strategy to drive innovation in radiology, including...

For Shared Decision-Making, Telemedicine…

Telemedicine may be just as effective as in-person visits when it comes to shared decision-making and communication for patients undergoing a first-time surgery consultation, according to a study published as...

Veradigm Announces Strategic Investment …

Veradigm Inc. (NASDAQ: MDRX), formerly Allscripts Healthcare Solutions, Inc., announced an investment in Holmusk, a global behavioral health real-world evidence and data analytics company, as part of Holmusk's $45 million...